Darren Schmidt is a Nephrology physician affiliated with University of New Mexico. OpenAlex indexes 60 publications with 619 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
University Of New Mexico- Hsc Division Of Nephrology
Albuquerque, NM 871318296
Telephone
970-272-0407Provider last certified this registry record 23 Oct 2024.
Clinical trials
- Impact of Screening Patients With HIV for Kidney Disease
Sponsor: University of Mississippi Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year202311 payments
- Amgen Inc.Program year20231 payment
- AstraZeneca Pharmaceuticals LPProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
66.1%Loop diuretic15.9%Furosemide73%Bumetanide16%Torsemide11%Part D<11 patientsAngiotensin receptor blocker (ARB)14.7%Losartan Potassium58%Irbesartan24%Telmisartan18%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
13.2%SGLT2 inhibitor6.8%Jardiance67%Farxiga33%Part D<11 patientsVitamin D3 Analog3.3%Calcitriol100%Part D<11 patients+ 1 more class in this area
Other
9.2%Phosphate Binder9.2%Sevelamer Carbonate100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Population Level Effects of COVID-19 Disease (C19D) and Vaccination (C19V) on eGFR
Journal of the American Society of Nephrology
2025 - COVID-19 Disease (C19D), Vaccination (C19V), and Vascular Access Complications Among Patients on Hemodialysis
Journal of the American Society of Nephrology
2025 - Membranous-Like Glomerulopathy with Masked IgG Kappa Deposits: A Case Series
Journal of the American Society of Nephrology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Mauricio Tohen, MD, DRPH, MBA
University of New Mexico
Howard Yonas, MD
University of New Mexico
Rhoshel Lenroot, MD
University of New Mexico
Mark Unruh, MD
University of New Mexico
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”